Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...

While we continue to believe blood-based testing is inferior to Cologuard, approval of this ... tech environments continues to rise. Within information technology, we remain careful in our risk ...

In the initial 10 years since launch, the Cologuard test was used more than 16 million times. Important Information About the Cologuard Test Do not use the Cologuard test if you have had precancer ...

The researchers used publicly available data from companies such as Guardant Health, Exact Sciences, and Geneoscopy to determine possible effects of blood-based tests.

While not as accurate as Cologuard, this test may prove to be ... This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by ...

Negative security selection within health care, information technology ... maker of the noninvasive colorectal cancer screening test Cologuard®. Shares fell in the first half of the year due ...

As November begins, so does Movember, the annual movement encouraging men to grow mustaches to spark conversations and raise ...